chrisvoncsefalvay/vaers-outcomes huggingface dataset:
19th Mar - Day 1 - Slight tightness at the area of injection 20th Mar - Day 2 - no symptom 21st Mar - Day 3 - no symptom 22nd Mar - Day 4 - no symptom 23rd Mar - Day 5 - no symptom 24th Mar - Day 6 - irritated throat after dinner 25th Mar - Day 7 - Sore throat, ear ache, full body and joints ache, temperature between 99 and 101, spoke to NP, was ordered Covid test 26th Mar - Day 8 - Sore throat (throat hurts while swallowing), body & joints ache, feverish (no fever),  27th Mar - Day 9 - Sore throat (throat hurts while swallowing), body & joints ache, feverish (no fever),
Patient received third dose , Pfizer, booster. After administration , switching to other arm for flu shot, patients stated that he felt lightheaded and then fainted. Was out for approximately 15 seconds. Put a cold rag on the back of his neck and called for help from pharmacy. Technician gave patient water and diet with patient. Patient called his mother to come pick him up.
Pregnant and wanted to be put on the registry; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and wanted to be put on the registry) in an adult female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (No reported medical history.).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. The patient's last menstrual period was on an unknown date and the estimated date of delivery was 06-Jan-2021. On an unknown date, the patient experienced MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and wanted to be put on the registry). The delivery occurred on an unknown date, which was reported as Unknown. For neonate 1, The outcome was reported as Unknown. At the time of the report, MATERNAL EXPOSURE DURING PREGNANCY (Pregnant and wanted to be put on the registry) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No Concomitant medications was provided by the reporter.  No Treatment medications was provided by the reporter.   Most recent FOLLOW-UP information incorporated above includes: On 31-Dec-2020: Internal review on 26-Jul-2021 resulted in updates to the pregnancy details.; Reporter's Comments: This is a case of product exposure during pregnancy with no associated AEs for this female patient. Patient will continue to be contacted for further monitoring of AEs during the pregnancy.
Employee called in sick the day after vaccine, missed 4 days, went to doctor and reported positive COVID-19 test and illness with symptoms of COVID-19.
Initial case was received on 06 August 2010 from the patient's mother. An 18 year old female patient received an injection of MENACTRA (or "MENOMUNE") (lot number unknown) in "2008." Approximately "2 hours later" the patient went jogging and fainted. It was unknown if she received any other vaccinations on the same date or within 4 weeks. The patient had no illness at the time of vaccination. Her pre-existing medical conditions included a latex allergy, but no other conditions were reported. The patient had recovered from fainting at an unspecified time. Documents held by sender: None. The mother also reported an adverse event for son captured in linked case 2010-04268.
Chills and headache 26 hours after the 2nd shot. Lasted couple of hours. Took Tylenol..
Neck pain and stiffness from settling in muscles around neck and shoulder, nerve pain when moving head forward and backward, nerve pain from injection  site down arm into elbow and wrist, muscle cramping and stretching.
MMR given intradermal. Redness about 1.0 inch around INJECTION site.
Symptoms: chills, upset stomach, body aches, injection site sore. symptoms lasted 2 days.
arm was red; very swollen lymph nodes; This spontaneous case was reported by a patient and describes the occurrence of ERYTHEMA (arm was red) and VACCINATION SITE LYMPHADENOPATHY (very swollen lymph nodes) in a 74-year-old female patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 vaccination.     The patient never had COVID positive test or diagnosis.  Previously administered products included for Product used for unknown indication: Flu vaccination (In fall) in 2020 and Flu vaccination (In fall) in 2021. Past adverse reactions to the above products included No adverse event with Flu vaccination and Flu vaccination. Concurrent medical conditions included Sulfonamide allergy (Sulfa drugs allergy), Hypercholesterolemia (No changes noticed after vaccination, condition present before vaccination), Arrhythmia (No changes noticed after vaccination, condition present before vaccination) and Arthritis (No changes noticed after vaccination, condition present before vaccination). Concomitant products included INFLUENZA VACCINE (FLU [INFLUENZA VACCINE]) and SIMVASTATIN for an unknown indication.    On 06-Oct-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (arm was red) and VACCINATION SITE LYMPHADENOPATHY (very swollen lymph nodes). The patient was treated with LORATADINE (CLARITINE) at an unspecified dose and frequency and PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, ERYTHEMA (arm was red) and VACCINATION SITE LYMPHADENOPATHY (very swollen lymph nodes) had resolved.            Concomitant medications also included Hidrcor and Clovividol. It was reported that 24 hours later her arm was red, she had very swollen lymph nodes at the injection site. On 05-Mar-2021, patient received first dose of Moderna vaccine, lot number and dose were not reported.  On 05-Apr-2021, patient received second dose of Moderna vaccine, lot number and dose were not reported.  In Nov 2021, patient received Third dose of Moderna vaccine, lot number and dose were not reported.  In Apr 2022, patient received Fourth dose of Moderna vaccine, lot number and dose were not reported. On 06-Oct-2022, the patient received flu vaccine but on different arm.   This case was linked to MOD-2022-657572 (Patient Link).
Information has been received from a nurse concerning a female patient with diabetes who on 14-SEP-2009 was vaccinated with the second dose of PNEUMOVAX 23, 0.5ml SC in left arm.  The nurse reported the patient received the first dose in approximately SEP-2004.  Concomitant therapy included influenza virus vaccine (unspecified) received on 14-SEP-2009 which was given at a separate site.  The nurse reported that on the evening of 14-SEP-2009, the patient developed an axillary knot.  The patient was seen in the office on 15-SEP-2009 and had a temperature of 101.3 degrees F which started on 15-SEP-2009.  She developed an irregular shaped red raised patch in front of the injection site but not exactly at site.  At the time of the report the patient had not recovered.  This is one of several reports received from the same source.  Additional information has been requested.
The pt experienced a swollen and red left thigh. Treated with Augmentin and warm compresses to the area.
Two reactions: First, the onset of chronic migraines. This happened July 3 and continues. I have not had a migraine for 40 years and  I only had one then. They are chronic now. I had a CAT scan (normal) and I am scheduled for an MRI.  The second was on Monday July 12, 2021. I experienced sudden and severe pain in my heart, the pain was severe and debilitating and I immediately went to the ER. The pain subsided within minutes. All tests revealed no heart attack and a stress test confirmed a healthy heart.
He said that he doesn't feel very well after the first dose.; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) for a Pfizer sponsored program.  A male patient received bnt162b2 (BNT162B2), administration date 13Apr2021 (Batch/Lot number: unknown) as dose 1, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: MALAISE (non-serious) with onset 13Apr2021, outcome "unknown", described as "He said that he doesn't feel very well after the first dose.".  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient initially received Johnson & Johnson COVID-19 vaccine on 3/5/2021. Patient reported to a Pfizer vaccine clinic on 3/26/2021 and received a vaccine there as well. Patient should not have a received a Pfizer vaccine. Patient did not report any adverse reaction.
This is a spontaneous report from a non-contactable consumer (parent). A male patient of an unspecified age receive TRUMENBA, via an unspecified route of administration on an unspecified date at single dose for immunization. The patient's medical history and concomitant medications were not reported. It was reported that the patient has been 'sick' for 7 years most likely due to the vaccine. The outcome of the event was unknown. No follow-up attempts are possible, information about batch number cannot be obtained.
COVID-19 illness after receiving dose one and dose 2 of COVID vaccine (Pfizer). On 4/27 developed the following symptoms: cough, headache, sore/scratchy throat, congestion, runny nose, eye pressure, and myalgia. COVID test confirmed COVID-19 infection. Vaccinated with Pfizer COVID vaccine as follows: dose 1 on 12/18/2020, dose 2 on 1/8/2021.
Acute nonintractable headache, unspecified headache type  2. Sinus pressure
Nurse reported that patient developed an injection site reaction characterized by redness and swelling. The patient recovered. This is 1 of 3 patients from this facility who experienced an adverse event following receipt of Acel-Imune lot 464-307.
Developed localized swelling and itchy rash at injection site; warm to touch - lasted almost 10 days Also, about 1-2 days after rash presented, I had significant paint in right knee - thought might be a symptom of my developing arthritis but pain escalated considerably and in another 2-3 days could not walk without severe pain.  Pain subsided in 4-5 days and after a week was gone.  Did not speak to doc as had placed call (4/8-9) to discuss what I thought was escalating arthritis pain (didn't connect to vaccine) but still haven't heard back.
Post vaccination, the patient experienced mild chickenpox. Another patient was reported with a similar experience. No further information is available.
lt arm became swollen; reddish-purple discoloration around site of vax; refused to move arm for 24 hrs; APAP did not relieve discomfort; arm sore & swollen; t100.3;
Nurses were called to designated client waiting area in parking lot after vaccine given.  Client c/o not being able to feel/lift hand and numbness/tingling up to shoulder where vaccine was given.
Information has been received from a health professional concerning a school age male patient who was vaccinated with a dose of varicella virus vaccine live. In approximately March 2006 the patient developed a mild case of breakthrough varicella with less than 50 lesions. Unspecified medical attention was sought. Subsequently, the patient recovered. There was no product quality complaint involved.
After vaccine administered, patient felt warm. Next day: swelling around injection site, itchy, red.
kept waking up; feels like a small cold; chills; injection site has been hurting; This spontaneous case was reported by a consumer and describes the occurrence of POOR QUALITY SLEEP (kept waking up), FEELING COLD (feels like a small cold), CHILLS (chills) and VACCINATION SITE PAIN (injection site has been hurting) in a 21-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 017B21A) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2021, the patient experienced POOR QUALITY SLEEP (kept waking up), FEELING COLD (feels like a small cold), CHILLS (chills) and VACCINATION SITE PAIN (injection site has been hurting). The patient was treated with PARACETAMOL (TYLENOL) for Cold, at an unspecified dose and frequency. At the time of the report, POOR QUALITY SLEEP (kept waking up), FEELING COLD (feels like a small cold), CHILLS (chills) and VACCINATION SITE PAIN (injection site has been hurting) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant product use was not provided by the reporter.
Burning and tingling pain on left side of head and face getting progressively worse. Hurts worse to move facial muscles or touch skin at area. No lesions.
Difficulty swallowing, 30 minutes after vaccine was administered. Enlarged tongue, difficulty talking. Episodes lasted less than 1 minute and occured 4-5 times over 2 hours. No difficulty breathing, HR was not elevated. BP, pulse ox and temperature were normal.
On the 27th of February I had severe intense chest pain it lasted for about 1 hour. I went to my PCP who ordered CT angiogram 3 days later, by time I had the test the symptoms had resolved. The results showed no signs of coronary disease. I was told that it was cardiomyositis.
Dose given without powder mixed; Dose given without powder mixed; This case was reported by a nurse via sales rep and described the occurrence of inappropriate preparation of medication in a patient who received Men ACWY-CRM NVS (Menveo) for prophylaxis.   On an unknown date, the patient received Menveo. On an unknown date, unknown after receiving Menveo, the patient experienced inappropriate preparation of medication and inappropriate dose of vaccine administered. On an unknown date, the outcome of the inappropriate preparation of medication and inappropriate dose of vaccine administered were unknown.  Additional details were provided as follows: The age at vaccination was not reported. The Menveo vaccine was mixed improperly dose given without powder mixed, which led to inappropriate preparation of medication and inappropriate dose of vaccine administered. The reporter did not consent to follow up.
PERSISTED MILD HEADACHE; This spontaneous report received from a patient concerned a 69 year old male. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 1805018 expiry: UNKNOWN) dose was not reported, administered on 26-MAR-2021 for prophylactic vaccination. No concomitant medications were reported. On 26-MAR-2021, the subject experienced persisted mild headache. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from persisted mild headache. This report was non-serious.
pt recvd vax & 2 hrs later began exp flushing, chills, nausea, hot flashes, lt sided jaw pain, ringing in lt ear, tearing of lt eye, lack of taste & extreme drowsiness; devel weakness & numbness; facial palsy; dx bell's palsy;
We had an Covid vaccine event at a low income apartment.  We checked the database but miss read his birthday and gave him the shot.  Patient  wanted the shot so he could get the $150 gift card incentive.
This spontaneous report was received from a registered nurse refers to a currently 5 year old patient of unknown gender. On an unknown date, the vaccine PROQUAD (Merck) was improperly stored. On an unknown date, the patient was vaccinated with PROQUAD (Merck) (dose, route and lot # were not reported). No adverse effects reported. At the time of the report the action taken was not reported. Additional information has been requested.
I got bumps. All over both arms; This is a spontaneous report from a contactable other HCP (patient). This 50-year-old male patient received bnt162b2 (COMIRNATY) at the age of 50-year-old on 20May2021 (Lot: unknown) as single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID-19. Medical history included Known allergies: Penalisan. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Any other medications the patient received within 2 weeks of vaccination was on record but unspecified. After the covid 19 vaccine given, patient got bumps on 27May2021 at 12:00 PM. That need to be biopsy now. All over both arms. The event was serious due to Disabling/Incapacitating/Disability or permanent damage. The adverse event result in Doctor or other healthcare professional office/clinic visit. Treatment received for the adverse event included Biopsy bloodwork creame. Since the vaccination, the patient has not been tested for COVID-19. The outcome of the event was unknown.  Information about lot/batch number has been requested.; Sender's Comments: Based on the temporal relationship, the association between the event bumps with COMIRNATY use can not be fully excluded.  The impact of this report on the benefit/risk profile of the Pfizer product is evaluated as part of Pfizer procedures for safety evaluation, including the review and analysis of aggregate data for adverse events. Any safety concern identified as part of this review, as well as any appropriate action in response, will be promptly notified to regulatory authorities, Ethics Committees, and Investigators, as appropriate.
This spontaneous case was reported by a consumer and describes the occurrence of ASTHENIA (Feeling weak a day or so) in an 84-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 013L20A) for COVID-19 vaccination. Concurrent medical conditions included Hypertension (blood pressure), Hyperlipidemia (cholesterol) and Pain.Concomitant products included AMLODIPINE BESILATE (AMLODIPINE [AMLODIPINE BESILATE]) for Blood pressure, PRAVASTATIN SODIUM (PRAVASTATIN [PRAVASTATIN SODIUM]) for Cholesterol, MELOXICAM for Pain.On 26-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In January 2021, the patient experienced ASTHENIA (Feeling weak a day or so). At the time of the report, ASTHENIA (Feeling weak a day or so) outcome was unknown. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.No treatment drug details was reported.  This case was linked to MOD-2021-388271 (Patient Link).
This patient had severe abdominal pain, flu-like discomfort, severity greater on 01/01/01. Unable to sleep due to abdominal pain, and bloating.
Report an adverse reaction; This spontaneous case was reported by a consumer and describes the occurrence of ADVERSE DRUG REACTION (Report an adverse reaction) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event (history not reported).    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced ADVERSE DRUG REACTION (Report an adverse reaction). At the time of the report, ADVERSE DRUG REACTION (Report an adverse reaction) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route) was unknown.       Very limited information regarding this event has been provided at this time. Further information has been requested.   Reporter did not allow further contact; Sender's Comments: Very limited information regarding this event has been provided at this time. Further information has been requested.
Both arms where injections were given are hot to touch, raised, rash-like.  Pt was scratching injections.
pityriasis rosea; This is a spontaneous report from a contactable consumer or other non hcp (Patient). A 67-years-old patient of an unspecified gender received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number was not reported) via an unspecified route of administration on Mar2021 (at the age of 67-year-old) as DOSE 2, SINGLE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Patient had previously received first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, Lot number was not reported) via unspecified route of administration on Mar2021 (at the age of 67-year-old) as DOSE 1, SINGLE for covid-19 immunisation. Patient reported that she/he received the Pfizer vaccine (both doses) in Mar2021. A couple of weeks later patient developed what his/her dermatologist believed was pityriasis rosea. Patient still had it and will be returning for his/her third appointment to follow up. He/she was also concerned about who was at greatest risk for myocarditis. The clinical outcome of event was not recovered. The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
This spontaneous report as received from a nurse refers to a patient of unknown age and gender. There was no information regarding the patient's pertinent medical history, drug reactions, allergies or concomitant therapies provided. On 07-MAR-2017, the patient was vaccinated with incorrectly stored dose of M-M-R II (dose, frequency, route of administration were not reported, lot # L049314, expiration date 03-DEC-2017. No adverse effects were reported. Administered dose of vaccine experienced the temperature excursion of -14.4 degrees Celsius for 54 minutes. Data logger was involved. There were no previous excursions reported. This is one of several reports received from the same reporter. Additional information is not expected, all information has already been obtained.; Sender's Comments:  US-009507513-1611USA011831: US-009507513-1611USA004113: US-009507513-1705USA009742:
redness and swelling in the arm; redness and swelling in the arm; hot; hard; some drainage of the arm because it was smelly; This spontaneous case was reported by a health care professional and describes the occurrence of ERYTHEMA (redness and swelling in the arm), PERIPHERAL SWELLING (redness and swelling in the arm), FEELING HOT (hot), SKIN INDURATION (hard) and DRAINAGE (some drainage of the arm because it was smelly) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 047B21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-May-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced ERYTHEMA (redness and swelling in the arm), PERIPHERAL SWELLING (redness and swelling in the arm), FEELING HOT (hot), SKIN INDURATION (hard) and DRAINAGE (some drainage of the arm because it was smelly). At the time of the report, ERYTHEMA (redness and swelling in the arm), PERIPHERAL SWELLING (redness and swelling in the arm), FEELING HOT (hot), SKIN INDURATION (hard) and DRAINAGE (some drainage of the arm because it was smelly) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Concomitant medication was not reported. No treatment medication was reported.    This case was linked to US-MODERNATX, INC.-MOD-2021-128176, US-MODERNATX, INC.-MOD-2021-128305, US-MODERNATX, INC.-MOD-2021-128576, US-MODERNATX, INC.-MOD-2021-128612, US-MODERNATX, INC.-MOD-2021-128612, US-MODERNATX, INC.-MOD-2021-128649, US-MODERNATX, INC.-MOD-2021-128689 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-128176: US-MODERNATX, INC.-MOD-2021-128305: US-MODERNATX, INC.-MOD-2021-128576: US-MODERNATX, INC.-MOD-2021-128612: US-MODERNATX, INC.-MOD-2021-128649: US-MODERNATX, INC.-MOD-2021-128689: US-MODERNATX, INC.-MOD-2021-128612: